Login Register Cart 0
Generic placeholder image

Endocrine, Metabolic & Immune Disorders - Drug Targets

Editor-in-Chief

ISSN (Print): 1871-5303
ISSN (Online): 2212-3873

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Thyroid and Eye: Where They Meet in Clinical Practice

Author(s): Mervat M. El-Eshmawy* and Maha Shahin

Volume 20, Issue 1, 2020

Page: [39 - 49] Pages: 11

DOI: 10.2174/1871530319666190618120107

Price: $65

Abstract

Objective: Thyroid Hormones (TH) are essential for normal growth, development and continued optimal function of most of the body organs including the eye. TH signaling plays a central role in the regulation of retinal development and maturation. Deficiency in TH during fetal and early postnatal development impairs growth of the eye and proliferation of all retinal cell types. The present article reviews the most important topics of the different derangements in thyroid function and structure and its relation with eye diseases.

Methods: A literature search strategy was conducted for all English-language literature.

Results: From a clinical practice viewpoint, it should be mentioned that both hypothyroidism and hyperthyroidism are accompanied by ocular diseases i.e. thyroid-associated ophthalmopathy, diabetic retinopathy and age-related macular degeneration. Although the orbit and globe are not common sites for metastatic thyroid cancers, orbital metastasis may be the primary clinical manifestation of thyroid carcinoma. Finally, some medications as amiodarone may be accompanied by both thyroid dysfunction and adverse ocular events.

Conclusion: Thyroid disorders and eye diseases are interrelated through several mechanisms thus, awareness of this relation has a great impact on early diagnosis and treatment.

Keywords: Thyroid disorders, Graves’ ophthalmopathy, diabetic retinopathy, age-related macular degeneration, ocular metastasis, amiodarone.

« Previous Next »
Graphical Abstract

[1]
Kim, B. Thyroid hormone as a determinant of energy expenditure and the basal metabolic rate. Thyroid, 2008, 18(2), 141-144.
[http://dx.doi.org/10.1089/thy.2007.0266] [PMID: 18279014]
[2]
Morreale de Escobar, G.; Obregon, M.J.; Escobar del Rey, F. Role of thyroid hormone during early brain development. Eur. J. Endocrinol., 2004, 151(Suppl. 3), U25-U37.
[http://dx.doi.org/10.1530/eje.0.151u025] [PMID: 15554884]
[3]
Wagner, M.S.; Wajner, S.M.; Maia, A.L. The role of thyroid hormone in testicular development and function. J. Endocrinol., 2008, 199(3), 351-365.
[http://dx.doi.org/10.1677/JOE-08-0218] [PMID: 18728126]
[4]
Canaris, G.J.; Manowitz, N.R.; Mayor, G.; Ridgway, E.C. The Colorado thyroid disease prevalence study. Arch. Intern. Med., 2000, 160(4), 526-534.
[http://dx.doi.org/10.1001/archinte.160.4.526] [PMID: 10695693]
[5]
Aoki, Y.; Belin, R.M.; Clickner, R.; Jeffries, R.; Phillips, L.; Mahaffey, K.R. Serum TSH and total T4 in the United States population and their association with participant characteristics: National Health and Nutrition Examination Survey (NHANES 1999-2002). Thyroid, 2007, 17(12), 1211-1223.
[http://dx.doi.org/10.1089/thy.2006.0235] [PMID: 18177256]
[6]
Garmendia Madariaga, A.; Santos Palacios, S.; Guillén-Grima, F.; Galofré, J.C. The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis. J. Clin. Endocrinol. Metab., 2014, 99(3), 923-931.
[http://dx.doi.org/10.1210/jc.2013-2409] [PMID: 24423323]
[7]
Roberts, M.R.; Srinivas, M.; Forrest, D.; Morreale de Escobar, G.; Reh, T.A. Making the gradient: thyroid hormone regulates cone opsin expression in the developing mouse retina. Proc. Natl. Acad. Sci. USA, 2006, 103(16), 6218-6223.
[http://dx.doi.org/10.1073/pnas.0509981103] [PMID: 16606843]
[8]
Glaschke, A.; Weiland, J.; Del Turco, D.; Steiner, M.; Peichl, L.; Glösmann, M. Thyroid hormone controls cone opsin expression in the retina of adult rodents. J. Neurosci., 2011, 31(13), 4844-4851.
[http://dx.doi.org/10.1523/JNEUROSCI.6181-10.2011] [PMID: 21451022]
[9]
Vangheluwe, O.; Ducasse, A.; Vaudrey, C.; Maes, B.; Delisle, M.J. [Prevalence of ophthalmopathy in Basedow disease. Follow-up of patients one year following diagnosis of hyperthyroidism] J. Fr. Ophtalmol., 1994, 17(5), 331-338.
[PMID: 8089419]
[10]
Wu, J.; Yue, S.; Geng, J.; Liu, L.; Teng, W.; Liu, L.; Chen, L. Relationship between Diabetic Retinopathy and SubclinicalHypothyroidism: a meta-analysis. Sci. Rep., 2015, 20(5), 12212.
[11]
Chaker, L.; Buitendijk, G.H.; Dehghan, A.; Medici, M.; Hofman, A.; Vingerling, J.R.; Franco, O.H.; Klaver, C.C.; Peeters, R.P. Thyroid function and age-related macular degeneration: a prospective population-based cohort study--the Rotterdam Study. BMC Med., 2015, 13, 94.
[http://dx.doi.org/10.1186/s12916-015-0329-0] [PMID: 25903050]
[12]
Rocha Filho, F.D.; Lima, G.G.; Ferreira, F.V.; Lima, M.G.; Hissa, M.N. Orbital metastasis as primary clinical manifestation of thyroid carcinoma--case report and literature review. Arq. Bras. Endocrinol. Metabol, 2008, 52(9), 1497-1500.
[http://dx.doi.org/10.1590/S0004-27302008000900014] [PMID: 19197459]
[13]
Bogazzi, F.; Tomisti, L.; Bartalena, L.; Aghini-Lombardi, F.; Martino, E. Amiodarone and the thyroid: a 2012 update. J. Endocrinol. Invest., 2012, 35(3), 340-348.
[PMID: 22433945]
[14]
Uçakhan, O.O.; Kanpolat, A.; Ylmaz, N.; Ozkan, M. Amiodarone keratopathy: an in vivo confocal microscopy study. Eye Contact Lens, 2005, 31(4), 148-157.
[http://dx.doi.org/10.1097/01.ICL.0000165283.36659.35] [PMID: 16021002]
[15]
Brent, G.A. Mechanisms of thyroid hormone action. J. Clin. Invest., 2012, 122(9), 3035-3043.
[http://dx.doi.org/10.1172/JCI60047] [PMID: 22945636]
[16]
Flamant, F.; Baxter, J.D.; Forrest, D.; Refetoff, S.; Samuels, H.; Scanlan, T.S.; Vennström, B.; Samarut, J. International Union of Pharmacology. LIX. The pharmacology and classification of the nuclear receptor superfamily: thyroid hormone receptors. Pharmacol. Rev., 2006, 58(4), 705-711.
[http://dx.doi.org/10.1124/pr.58.4.3] [PMID: 17132849]
[17]
Peichl, L. Diversity of mammalian photoreceptor properties: adaptations to habitat and lifestyle? Anat. Rec. A Discov. Mol. Cell. Evol. Biol., 2005, 287(1), 1001-1012.
[http://dx.doi.org/10.1002/ar.a.20262] [PMID: 16200646]
[18]
Ng, L.; Ma, M.; Curran, T.; Forrest, D. Developmental expression of thyroid hormone receptor β2 protein in cone photoreceptors in the mouse. Neuroreport, 2009, 20(6), 627-631.
[http://dx.doi.org/10.1097/WNR.0b013e32832a2c63] [PMID: 19282790]
[19]
Lee, T.C.; Almeida, D.; Claros, N.; Abramson, D.H.; Cobrinik, D. Cell cycle-specific and cell type-specific expression of Rb in the developing human retina. Invest. Ophthalmol. Vis. Sci., 2006, 47(12), 5590-5598.
[http://dx.doi.org/10.1167/iovs.06-0063] [PMID: 17122153]
[20]
Hiroi, Y.; Kim, H.H.; Ying, H.; Furuya, F.; Huang, Z.; Simoncini, T.; Noma, K.; Ueki, K.; Nguyen, N.H.; Scanlan, T.S.; Moskowitz, M.A.; Cheng, S.Y.; Liao, J.K. Rapid nongenomic actions of thyroid hormone. Proc. Natl. Acad. Sci. USA, 2006, 103(38), 14104-14109.
[http://dx.doi.org/10.1073/pnas.0601600103] [PMID: 16966610]
[21]
Cheng, S.Y.; Leonard, J.L.; Davis, P.J. Molecular aspects of thyroid hormone actions. Endocr. Rev., 2010, 31(2), 139-170.
[http://dx.doi.org/10.1210/er.2009-0007] [PMID: 20051527]
[22]
Sawant, O.; Horton, A.M.; Shukla, M.; Rayborn, M.E.; Peachey, N.S.; Hollyfield, J.G.; Rao, S. Light-Regulated Thyroid Hormone Signaling Is Required for Rod Photoreceptor Development in the Mouse Retina. Invest. Ophthalmol. Vis. Sci., 2015, 56(13), 8248-8257.
[http://dx.doi.org/10.1167/iovs.15-17743] [PMID: 26720479]
[23]
Sevilla-Romero, E.; Muñoz, A.; Pinazo-Durán, M.D. Low thyroid hormone levels impair the perinatal development of the rat retina. Ophthalmic Res., 2002, 34(4), 181-191.
[http://dx.doi.org/10.1159/000063885] [PMID: 12297689]
[24]
Newell, F.W.; Diddie, K.R. [Typical monochromacy, congenital deafness, and resistance to intracellular action of thyroid hormone (author’s transl)] Klin. Monatsbl. Augenheilkd., 1977, 171(5), 731-734.
[PMID: 304503]
[25]
Dentice, M.; Salvatore, D. Deiodinases: the balance of thyroid hormone: local impact of thyroid hormone inactivation. J. Endocrinol., 2011, 209(3), 273-282.
[http://dx.doi.org/10.1530/JOE-11-0002] [PMID: 21398344]
[26]
Ng, L.; Lyubarsky, A.; Nikonov, S.S.; Ma, M.; Srinivas, M.; Kefas, B.; St Germain, D.L.; Hernandez, A.; Pugh, E.N., Jr; Forrest, D. Type 3 deiodinase, a thyroid-hormone-inactivating enzyme, controls survival and maturation of cone photoreceptors. J. Neurosci., 2010, 30(9), 3347-3357.
[http://dx.doi.org/10.1523/JNEUROSCI.5267-09.2010] [PMID: 20203194]
[27]
Ma, H.; Thapa, A.; Morris, L.; Redmond, T.M.; Baehr, W.; Ding, X.Q. Suppressing thyroid hormone signaling preserves cone photoreceptors in mouse models of retinal degeneration. Proc. Natl. Acad. Sci. USA, 2014, 111(9), 3602-3607.
[http://dx.doi.org/10.1073/pnas.1317041111] [PMID: 24550448]
[28]
Yang, F.; Ma, H.; Belcher, J.; Butler, M.R.; Redmond, T.M.; Boye, S.L.; Hauswirth, W.W.; Ding, X.Q. Targeting iodothyronine deiodinases locally in the retina is a therapeutic strategy for retinal degeneration. FASEB J., 2016, 30(12), 4313-4325.
[http://dx.doi.org/10.1096/fj.201600715R] [PMID: 27623928]
[29]
Ma, H.; Yang, F.; Butler, M.R.; Belcher, J.; Redmond, T.M.; Placzek, A.T.; Scanlan, T.S.; Ding, X-Q. Inhibition of thyroid hormone receptor locally in the retina is a therapeutic strategy for retinal degeneration. FASEB J., 2017, 31(8), 3425-3438.
[http://dx.doi.org/10.1096/fj.201601166RR] [PMID: 28428265]
[30]
Zambrano, A.; García-Carpizo, V.; Gallardo, M.E.; Villamuera, R.; Gómez-Ferrería, M.A.; Pascual, A.; Buisine, N.; Sachs, L.M.; Garesse, R.; Aranda, A. The thyroid hormone receptor β induces DNA damage and premature senescence. J. Cell Biol., 2014, 204(1), 129-146.
[http://dx.doi.org/10.1083/jcb.201305084] [PMID: 24395638]
[31]
Park, J.W.; Zhao, L.; Cheng, S.Y. Inhibition of estrogen-dependent tumorigenesis by the thyroid hormone receptor β in xenograft models. Am. J. Cancer Res., 2013, 3(3), 302-311.
[PMID: 23841029]
[32]
Werner, S.C.; Ingbar, S.H.; Braverman, L.E.; Utiger, R.D. The Thyroid: A Fundamental and Clinical Text; 7th; Werner and Ingbar's: Philadelphia, PA: Lippincott-Raven, 1996.
[33]
Bartley, G.B.; Fatourechi, V.; Kadrmas, E.F.; Jacobsen, S.J.; Ilstrup, D.M.; Garrity, J.A.; Gorman, C.A. Long-term follow-up of Graves ophthalmopathy in an incidence cohort. Ophthalmology, 1996, 103(6), 958-962.
[http://dx.doi.org/10.1016/S0161-6420(96)30579-4] [PMID: 8643255]
[34]
Douglas, R.S.; Gupta, S. The pathophysiology of thyroid eye disease: implications for immunotherapy. Curr. Opin. Ophthalmol., 2011, 22(5), 385-390.
[http://dx.doi.org/10.1097/ICU.0b013e3283499446] [PMID: 21730841]
[35]
Kalmann, R.; Mourits, M.P. Late recurrence of unilateral graves orbitopathy on the contralateral side. Am. J. Ophthalmol., 2002, 133(5), 727-729.
[http://dx.doi.org/10.1016/S0002-9394(02)01390-9] [PMID: 11992884]
[36]
Smith, T.J.; Bahn, R.S.; Gorman, C.A. Connective tissue, glycosaminoglycans, and diseases of the thyroid. Endocr. Rev., 1989, 10(3), 366-391.
[http://dx.doi.org/10.1210/edrv-10-3-366] [PMID: 2673756]
[37]
Davies, T.F. Graves’ disease: Pathogenesis. In: Werner & Ingbar’s The Thyroid; Braverman, L.E.; Utiger, R.D., Eds.; Lippincott, Williams & Wilkins: Philadelphia, 2000; p. 518.
[38]
Perros, P.; Crombie, A.L.; Matthews, J.N.; Kendall-Taylor, P. Age and gender influence the severity of thyroid-associated ophthalmopathy: a study of 101 patients attending a combined thyroid-eye clinic. Clin. Endocrinol. (Oxf.), 1993, 38(4), 367-372.
[http://dx.doi.org/10.1111/j.1365-2265.1993.tb00516.x] [PMID: 8319368]
[39]
Prummel, M.F.; Wiersinga, W.M. Smoking and risk of Graves’ disease. JAMA, 1993, 269(4), 479-482.
[http://dx.doi.org/10.1001/jama.1993.03500040045034] [PMID: 8419666]
[40]
Acharya, S.H.; Avenell, A.; Philip, S.; Burr, J.; Bevan, J.S.; Abraham, P. Radioiodine therapy (RAI) for Graves’ disease (GD) and the effect on ophthalmopathy: a systematic review. Clin. Endocrinol. (Oxf.), 2008, 69(6), 943-950.
[http://dx.doi.org/10.1111/j.1365-2265.2008.03279.x] [PMID: 18429949]
[41]
Grzesiuk, W.; Szydlarska, D.; Pragacz, A.; Bar-Andziak, E. Thyroid-associated orbitopathy in patients with Hashimoto’s thyroiditis: a case report. Pol. Arch. Med. Wewn., 2008, 118(5), 318-321.
[http://dx.doi.org/10.20452/pamw.400] [PMID: 18619184]
[42]
Kırmızıbekmez, H.; Yeşiltepe Mutlu, R.G.; Dursun, F.; Gunay, M. Atypical Presentation of Hashimoto’s Disease in an Adolescent: Thyroid-Associated Ophthalmopathy. J. Clin. Res. Pediatr. Endocrinol., 2014, 6(4), 262-265.
[http://dx.doi.org/10.4274/jcrpe.1450] [PMID: 25541900]
[43]
Bahn, R.S. Graves’ ophthalmopathy. N. Engl. J. Med., 2010, 362(8), 726-738.
[http://dx.doi.org/10.1056/NEJMra0905750] [PMID: 20181974]
[44]
Burch, H.B.; Wartofsky, L. Graves’ ophthalmopathy: current concepts regarding pathogenesis and management. Endocr. Rev., 1993, 14(6), 747-793.
[PMID: 8119236]
[45]
Stadlmayr, W.; Spitzweg, C.; Bichlmair, A.M.; Heufelder, A.E. TSH receptor transcripts and TSH receptor-like immunoreactivity in orbital and pretibial fibroblasts of patients with Graves’ ophthalmopathy and pretibial myxedema. Thyroid, 1997, 7(1), 3-12.
[http://dx.doi.org/10.1089/thy.1997.7.3] [PMID: 9086563]
[46]
Spitzweg, C.; Joba, W.; Hunt, N.; Heufelder, A.E. Analysis of human thyrotropin receptor gene expression and immunoreactivity in human orbital tissue. Eur. J. Endocrinol., 1997, 136(6), 599-607.
[http://dx.doi.org/10.1530/eje.0.1360599] [PMID: 9225723]
[47]
Valyasevi, R.W.; Erickson, D.Z.; Harteneck, D.A.; Dutton, C.M.; Heufelder, A.E.; Jyonouchi, S.C.; Bahn, R.S. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor. J. Clin. Endocrinol. Metab., 1999, 84(7), 2557-2562.
[http://dx.doi.org/10.1210/jc.84.7.2557] [PMID: 10404836]
[48]
Tsui, S.; Naik, V.; Hoa, N.; Hwang, C.J.; Afifiyan, N.F.; Sinha Hikim, A.; Gianoukakis, A.G.; Douglas, R.S.; Smith, T.J. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J. Immunol., 2008, 181(6), 4397-4405.
[http://dx.doi.org/10.4049/jimmunol.181.6.4397] [PMID: 18768899]
[49]
Marcocci, C.; Marinò, M. Treatment of mild, moderate-to-severe and very severe Graves’ orbitopathy. Best Pract. Res. Clin. Endocrinol. Metab., 2012, 26(3), 325-337.
[http://dx.doi.org/10.1016/j.beem.2011.11.005] [PMID: 22632369]
[50]
Skalka, H.W.; Prchal, J.T. Effect of corticosteroids on cataract formation. Arch. Ophthalmol., 1980, 98(10), 1773-1777.
[http://dx.doi.org/10.1001/archopht.1980.01020040625007] [PMID: 7425901]
[51]
Tripathi, R.C.; Parapuram, S.K.; Tripathi, B.J.; Zhong, Y.; Chalam, K.V. Corticosteroids and glaucoma risk. Drugs Aging, 1999, 15(6), 439-450.
[http://dx.doi.org/10.2165/00002512-199915060-00004] [PMID: 10641955]
[52]
Garber, J.R.; Cobin, R.H.; Gharib, H.; Hennessey, J.V.; Klein, I.; Mechanick, J.I.; Pessah-Pollack, R.; Singer, P.A.; Woeber, K.A. American Association of Clinical Endocrinologists and American Thyroid Association Taskforce on Hypothyroidism in Adults. Clinical practice guidelines for hypothyroidism in adults: cosponsored by the American Association of Clinical Endocrinologists and the American Thyroid Association. Endocr. Pract., 2012, 18(6), 988-1028.
[http://dx.doi.org/10.4158/EP12280.GL] [PMID: 23246686]
[53]
Perros, P.; McCrimmon, R.J.; Shaw, G.; Frier, B.M. Frequency of thyroid dysfunction in diabetic patients: value of annual screening. Diabet. Med., 1995, 12(7), 622-627.
[http://dx.doi.org/10.1111/j.1464-5491.1995.tb00553.x] [PMID: 7554786]
[54]
Uzunlulu, M.; Yorulmaz, E.; Oguz, A. Prevalence of subclinical hypothyroidism in patients with metabolic syndrome. Endocr. J., 2007, 54(1), 71-76.
[http://dx.doi.org/10.1507/endocrj.K06-124] [PMID: 17102569]
[55]
Jones, D.D.; May, K.E.; Geraci, S.A. Subclinical thyroid disease. Am. J. Med., 2010, 123(6), 502-504.
[http://dx.doi.org/10.1016/j.amjmed.2009.12.023] [PMID: 20569751]
[56]
La Vignera, S.; Condorelli, R.; Vicari, E.; Calogero, A.E. Endothelial dysfunction and subclinical hypothyroidism: a brief review. J. Endocrinol. Invest., 2012, 35(1), 96-103.
[PMID: 22186427]
[57]
Caraccio, N.; Ferrannini, E.; Monzani, F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J. Clin. Endocrinol. Metab., 2002, 87(4), 1533-1538.
[http://dx.doi.org/10.1210/jcem.87.4.8378] [PMID: 11932277]
[58]
Yamada, M.; Hiratsuka, Y.; Roberts, C.B.; Pezzullo, M.L.; Yates, K.; Takano, S.; Miyake, K.; Taylor, H.R. Prevalence of visual impairment in the adult Japanese population by cause and severity and future projections. Ophthalmic Epidemiol., 2010, 17(1), 50-57.
[http://dx.doi.org/10.3109/09286580903450346] [PMID: 20100100]
[59]
Zhang, X.; Saaddine, J.B.; Chou, C.F.; Cotch, M.F.; Cheng, Y.J.; Geiss, L.S.; Gregg, E.W.; Albright, A.L.; Klein, B.E.; Klein, R. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA, 2010, 304(6), 649-656.
[http://dx.doi.org/10.1001/jama.2010.1111] [PMID: 20699456]
[60]
Yang, G.R.; Yang, J.K.; Zhang, L.; An, Y.H.; Lu, J.K. Association between subclinical hypothyroidism and proliferative diabetic retinopathy in type 2 diabetic patients: a case-control study. Tohoku J. Exp. Med., 2010, 222(4), 303-310.
[http://dx.doi.org/10.1620/tjem.222.303] [PMID: 21139382]
[61]
Yang, J.K.; Liu, W.; Shi, J.; Li, Y.B. An association between subclinical hypothyroidism and sight-threatening diabetic retinopathy in type 2 diabetic patients. Diabetes Care, 2010, 33(5), 1018-1020.
[http://dx.doi.org/10.2337/dc09-1784] [PMID: 20150298]
[62]
Kim, B.Y.; Kim, C.H.; Jung, C.H.; Mok, J.O.; Suh, K.I.; Kang, S.K. Association between subclinical hypothyroidism and severe diabetic retinopathy in Korean patients with type 2 diabetes. Endocr. J., 2011, 58(12), 1065-1070.
[http://dx.doi.org/10.1507/endocrj.EJ11-0199] [PMID: 21931224]
[63]
Ramis, J.N.; Artigas, C.F.; Santiago, M.A.; Mañes, F.J.; Canonge, R.S.; Comas, L.M. Is there a relationship between TSH levels and diabetic retinopathy in the Caucasian population? Diabetes Res. Clin. Pract., 2012, 97(3), e45-e47.
[http://dx.doi.org/10.1016/j.diabres.2012.05.015] [PMID: 22717499]
[64]
Chen, H.S.; Wu, T.E.; Jap, T.S.; Lu, R.A.; Wang, M.L.; Chen, R.L.; Lin, H.D. Subclinical hypothyroidism is a risk factor for nephropathy and cardiovascular diseases in Type 2 diabetic patients. Diabet. Med., 2007, 24(12), 1336-1344.
[http://dx.doi.org/10.1111/j.1464-5491.2007.02270.x] [PMID: 17941864]
[65]
Qi, Q.; Zhang, Q.M.; Li, C.J.; Dong, R.N.; Li, J.J.; Shi, J.Y.; Yu, D.M.; Zhang, J.Y. Association of Thyroid-Stimulating Hormone Levels with Microvascular Complications in Type 2 Diabetes Patients. Med. Sci. Monit., 2017, 23(23), 2715-2720.
[http://dx.doi.org/10.12659/MSM.902006] [PMID: 28578377]
[66]
Popescu, T.; Moţa, M. Dyslipidemia and hypertension in patients with type 2 diabetes and retinopathy. Rom. J. Intern. Med., 2009, 47(3), 235-241.
[PMID: 20446438]
[67]
Masaki, H.; Nishikawa, M.; Urakami, M.; Yoshimura, M.; Toyoda, N.; Mori, Y.; Yoshikawa, N.; Inada, M. 3,3′,5′-Triiodothyronine inhibits collagen-induced human platelet aggregation. J. Clin. Endocrinol. Metab., 1992, 75(3), 721-725.
[PMID: 1517361]
[68]
Ishikawa, T.; Chijiwa, T.; Hagiwara, M.; Mamiya, S.; Hidaka, H. Thyroid hormones directly interact with vascular smooth muscle strips. Mol. Pharmacol., 1989, 35(6), 760-765.
[PMID: 2733694]
[69]
Chadarevian, R.; Bruckert, E.; Ankri, A.; Beucler, I.; Giral, P.; Turpin, G. Relationship between thyroid hormones and plasma D-dimer levels. Thromb. Haemost., 1998, 79(1), 99-103.
[http://dx.doi.org/10.1055/s-0037-1614228] [PMID: 9459332]
[70]
Költringer, P.; Eber, O.; Wakonig, P.; Klima, G.; Lind, P. Hypothyroidism and the influence on human blood rheology. J. Endocrinol. Invest., 1988, 11(4), 267-272.
[http://dx.doi.org/10.1007/BF03350150] [PMID: 3411087]
[71]
Maratou, E.; Hadjidakis, D.J.; Kollias, A.; Tsegka, K.; Peppa, M.; Alevizaki, M.; Mitrou, P.; Lambadiari, V.; Boutati, E.; Nikzas, D.; Tountas, N.; Economopoulos, T.; Raptis, S.A.; Dimitriadis, G. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur. J. Endocrinol., 2009, 160(5), 785-790.
[http://dx.doi.org/10.1530/EJE-08-0797] [PMID: 19141606]
[72]
Hadjadj, S.; Péan, F.; Gallois, Y.; Passa, P.; Aubert, R.; Weekers, L.; Rigalleau, V.; Bauduceau, B.; Bekherraz, A.; Roussel, R.; Dussol, B.; Rodier, M.; Marechaud, R.; Lefebvre, P.J.; Marre, M. Genesis France-Belgium Study. Different patterns of insulin resistance in relatives of type 1 diabetic patients with retinopathy or nephropathy: the Genesis France-Belgium Study. Diabetes Care, 2004, 27(11), 2661-2668.
[http://dx.doi.org/10.2337/diacare.27.11.2661] [PMID: 15505002]
[73]
Parvanova, A.; Iliev, I.; Filipponi, M.; Dimitrov, B.D.; Vedovato, M.; Tiengo, A.; Trevisan, R.; Remuzzi, G.; Ruggenenti, P. Insulin resistance and proliferative retinopathy: a cross-sectional, case-control study in 115 patients with type 2 diabetes. J. Clin. Endocrinol. Metab., 2004, 89(9), 4371-4376.
[http://dx.doi.org/10.1210/jc.2003-032076] [PMID: 15356034]
[74]
Yudkin, J.S. Abnormalities of coagulation and fibrinolysis in insulin resistance. Evidence for a common antecedent? Diabetes Care, 1999, 22(Suppl 3), C25-30. 26.
[http://dx.doi.org/10.1507/endocrj.47.77] [PMID: 10811296]
[75]
Kurioka, S.; Koshimura, K.; Murakami, Y.; Nishiki, M.; Kato, Y. Reverse correlation between urine nitric oxide metabolites and insulin resistance in patients with type 2 diabetes mellitus. Endocr. J., 2000, 47(1), 77-81.
[http://dx.doi.org/10.1507/endocrj.47.77] [PMID: 10811296]
[76]
Cikim, A.S.; Oflaz, H.; Ozbey, N.; Cikim, K.; Umman, S.; Meric, M.; Sencer, E.; Molvalilar, S. Evaluation of endothelial function in subclinical hypothyroidism and subclinical hyperthyroidism. Thyroid, 2004, 14(8), 605-609.
[http://dx.doi.org/10.1089/1050725041692891] [PMID: 15320973]
[77]
Jager, R.D.; Mieler, W.F.; Miller, J.W. Age-related macular degeneration. N. Engl. J. Med., 2008, 358(24), 2606-2617.
[http://dx.doi.org/10.1056/NEJMra0801537] [PMID: 18550876]
[78]
Hageman, G.S.; Luthert, P.J.; Victor Chong, N.H.; Johnson, L.V.; Anderson, D.H.; Mullins, R.F. An integrated hypothesis that considers drusen as biomarkers of immune-mediated processes at the RPE-Bruch’s membrane interface in aging and age-related macular degeneration. Prog. Retin. Eye Res., 2001, 20(6), 705-732.
[http://dx.doi.org/10.1016/S1350-9462(01)00010-6] [PMID: 11587915]
[79]
Kaarniranta, K.; Salminen, A. Age-related macular degeneration: activation of innate immunity system via pattern recognition receptors. J. Mol. Med. (Berl.), 2009, 87(2), 117-123.
[http://dx.doi.org/10.1007/s00109-008-0418-z] [PMID: 19009282]
[80]
Rosenfeld, P.J.; Brown, D.M.; Heier, J.S.; Boyer, D.S.; Kaiser, P.K.; Chung, C.Y.; Kim, R.Y. MARINA Study Group. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med., 2006, 355(14), 1419-1431.
[http://dx.doi.org/10.1056/NEJMoa054481] [PMID: 17021318]
[81]
Nguyen, D.H.; Luo, J.; Zhang, K.; Zhang, M. Current therapeutic approaches in neovascular age-related macular degeneration. Discov. Med., 2013, 15(85), 343-348.
[PMID: 23819948]
[82]
Thornton, J.; Edwards, R.; Mitchell, P.; Harrison, R.A.; Buchan, I.; Kelly, S.P. Smoking and age-related macular degeneration: a review of association. Eye (Lond.), 2005, 19(9), 935-944.
[http://dx.doi.org/10.1038/sj.eye.6701978] [PMID: 16151432]
[83]
Age-Related Eye Disease Study 2 Research Group. Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. JAMA, 2013, 309(19), 2005-2015.
[http://dx.doi.org/10.1001/jama.2013.4997] [PMID: 23644932]
[84]
Lim, L.S.; Mitchell, P.; Seddon, J.M.; Holz, F.G.; Wong, T.Y. Age-related macular degeneration. Lancet, 2012, 379(9827), 1728-1738.
[http://dx.doi.org/10.1016/S0140-6736(12)60282-7] [PMID: 22559899]
[85]
Gopinath, B.; Flood, V.M.; Louie, J.C.; Wang, J.J.; Burlutsky, G.; Rochtchina, E.; Mitchell, P. Consumption of dairy products and the 15-year incidence of age-related macular degeneration. Br. J. Nutr., 2014, 111(9), 1673-1679.
[http://dx.doi.org/10.1017/S000711451300408X] [PMID: 24502821]
[86]
Bromfield, S.; Keenan, J.; Jolly, P.; McGwin, G. Jr A suggested association between hypothyroidism and age-related macular degeneration. Curr. Eye Res., 2012, 37(6), 549-552.
[http://dx.doi.org/10.3109/02713683.2011.647223] [PMID: 22577773]
[87]
Klein, R.; Klein, B.E.; Jensen, S.C.; Cruickshanks, K.J.; Lee, K.E.; Danforth, L.G.; Tomany, S.C. Medication use and the 5-year incidence of early age-related maculopathy: the Beaver Dam Eye Study. Arch. Ophthalmol., 2001, 119(9), 1354-1359.
[http://dx.doi.org/10.1001/archopht.119.9.1354] [PMID: 11545642]
[88]
Age-Related Eye Disease Study Research Group. Risk factors associated with age-related macular degeneration. A case-control study in the age-related eye disease study: Age-Related Eye Disease Study Report Number 3. Ophthalmology, 2000, 107(12), 2224-2232.
[PMID: 11097601]
[89]
Douglas, I.J.; Cook, C.; Chakravarthy, U.; Hubbard, R.; Fletcher, A.E.; Smeeth, L. A case-control study of drug risk factors for age-related macular degeneration. Ophthalmology, 2007, 114(6), 1164-1169.
[http://dx.doi.org/10.1016/j.ophtha.2006.09.018] [PMID: 17544775]
[90]
Gopinath, B.; Liew, G.; Kifley, A.; Mitchell, P. Thyroid Dysfunction and Ten-Year Incidence of Age-Related Macular Degeneration. Invest. Ophthalmol. Vis. Sci., 2016, 1,57(13), 5273-5277.
[http://dx.doi.org/10.1167/iovs.16-19735]
[91]
Tsai, C.C.; Kao, S.C.; Cheng, C.Y.; Kau, H.C.; Hsu, W.M.; Lee, C.F.; Wei, Y.H. Oxidative stress change by systemic corticosteroid treatment among patients having active graves ophthalmopathy. Arch. Ophthalmol., 2007, 125(12), 1652-1656.
[http://dx.doi.org/10.1001/archopht.125.12.1652] [PMID: 18071117]
[92]
Mano, T.; Sinohara, R.; Sawai, Y.; Oda, N.; Nishida, Y.; Mokuno, T.; Kotake, M.; Hamada, M.; Masunaga, R.; Nakai, A.; Nagasaka, A. Effects of thyroid hormone on coenzyme Q and other free radical scavengers in rat heart muscle. J. Endocrinol., 1995, 145(1), 131-136.
[http://dx.doi.org/10.1677/joe.0.1450131] [PMID: 7798018]
[93]
Beatty, S.; Koh, H.; Phil, M.; Henson, D.; Boulton, M. The role of oxidative stress in the pathogenesis of age-related macular degeneration. Surv. Ophthalmol., 2000, 45(2), 115-134.
[http://dx.doi.org/10.1016/S0039-6257(00)00140-5] [PMID: 11033038]
[94]
Duncan, K.G.; Bailey, K.R.; Baxter, J.D.; Schwartz, D.M. The human fetal retinal pigment epithelium: A target tissue for thyroid hormones. Ophthalmic Res., 1999, 31(6), 399-406.
[http://dx.doi.org/10.1159/000055564] [PMID: 10474068]
[95]
Klein, I.; Danzi, S. Thyroid disease and the heart. Circulation, 2007, 116(15), 1725-1735.
[http://dx.doi.org/10.1161/CIRCULATIONAHA.106.678326] [PMID: 17923583]
[96]
Devdhar, M.; Ousman, Y.H.; Burman, K.D. Hypothyroidism. Endocrinol. Metab. Clin. North Am., 2007, 36(3), 595-615. v. [v.].
[http://dx.doi.org/10.1016/j.ecl.2007.04.008] [PMID: 17673121]
[97]
Vingerling, J.R.; Klaver, C.C.; Hofman, A.; de Jong, P.T. Epidemiology of age-related maculopathy. Epidemiol. Rev., 1995, 17(2), 347-360.
[http://dx.doi.org/10.1093/oxfordjournals.epirev.a036198] [PMID: 8654516]
[98]
Lin, S.Y.; Hsu, W.H.; Lin, C.L.; Lin, C.C.; Lin, J.M.; Chang, Y.L.; Hsu, C.Y.; Kao, C.H. Evidence for an Association between Macular Degeneration and Thyroid Cancer in the Aged Population. Int. J. Environ. Res. Public Health, 2018, 15(5), 902.
[http://dx.doi.org/10.3390/ijerph15050902] [PMID: 29751509]
[99]
Zhao, Z.G.; Guo, X.G.; Ba, C.X.; Wang, W.; Yang, Y.Y.; Wang, J.; Cao, H.Y. Overweight, obesity and thyroid cancer risk: a meta-analysis of cohort studies. J. Int. Med. Res., 2012, 40(6), 2041-2050.
[http://dx.doi.org/10.1177/030006051204000601] [PMID: 23321160]
[100]
Seddon, J.M.; Cote, J.; Davis, N.; Rosner, B. Progression of age-related macular degeneration: association with body mass index, waist circumference, and waist-hip ratio. Arch. Ophthalmol., 2003, 121(6), 785-792.
[http://dx.doi.org/10.1001/archopht.121.6.785] [PMID: 12796248]
[101]
Brandon, M.; Baldi, P.; Wallace, D.C. Mitochondrial mutations in cancer. Oncogene, 2006, 25(34), 4647-4662.
[http://dx.doi.org/10.1038/sj.onc.1209607] [PMID: 16892079]
[102]
Udar, N.; Atilano, S.R.; Memarzadeh, M.; Boyer, D.S.; Chwa, M.; Lu, S.; Maguen, B.; Langberg, J.; Coskun, P.; Wallace, D.C.; Nesburn, A.B.; Khatibi, N.; Hertzog, D.; Le, K.; Hwang, D.; Kenney, M.C. Mitochondrial DNA haplogroups associated with age-related macular degeneration. Invest. Ophthalmol. Vis. Sci., 2009, 50(6), 2966-2974.
[http://dx.doi.org/10.1167/iovs.08-2646] [PMID: 19151382]
[103]
Slamovits, T.L.; Mondzelewski, J.P.; Kennerdell, J.S. Thyroid carcinoma metastatic to the globe. Br. J. Ophthalmol., 1979, 63(3), 169-172.
[http://dx.doi.org/10.1136/bjo.63.3.169] [PMID: 435427]
[104]
Arat, Y.O.; Boniuk, M. Red lesions of the iris, choroid, and skin secondary to metastatic carcinoma of the thyroid: a review. Surv. Ophthalmol., 2007, 52(5), 523-528.
[http://dx.doi.org/10.1016/j.survophthal.2007.06.006] [PMID: 17719373]
[105]
Singh, U.; Kaushik, S.; Pandav, S.S.; Dogra, M.R.; Powari, M.; Das, A.; Hemachandra, M. Papillary carcinoma thyroid presenting as a choroidal metastasis. Report of a case and brief review of literature. Indian J. Ophthalmol., 2003, 51(1), 81-83.
[PMID: 12701869]
[106]
Jemal, A.; Siegel, R.; Ward, E.; Hao, Y.; Xu, J.; Murray, T.; Thun, M. J. Cancer statistics, 2008. CA Cancer J. Clin., 2008, 58(2), 71-96.
[http://dx.doi.org/10.3322/CA.2007.0010] [PMID: 18287387]
[107]
Avram, A.M.; Gielczyk, R.; Su, L.; Vine, A.K.; Sisson, J.C. Choroidal and skin metastases from papillary thyroid cancer: case and a review of the literature. J. Clin. Endocrinol. Metab., 2004, 89(11), 5303-5307.
[http://dx.doi.org/10.1210/jc.2004-0757] [PMID: 15531474]
[108]
Shaha, A.R.; Shah, J.P.; Loree, T.R. Differentiated thyroid cancer presenting initially with distant metastasis. Am. J. Surg., 1997, 174(5), 474-476.
[http://dx.doi.org/10.1016/S0002-9610(97)00158-X] [PMID: 9374217]
[109]
Bucerius, J.; Meyka, S.; Michael, B.; Biersack, H.J.; Eter, N. Papillary thyroid carcinoma with an uncommon spread of hematogenous metastases to the choroid and the skin. J. Natl. Med. Assoc., 2008, 100(1), 104-107.
[http://dx.doi.org/10.1016/S0027-9684(15)31183-4] [PMID: 18277817]
[110]
Tran, K.; Bigby, K.J.; Hughes, B.G.; Lee, L.; Allison, R. Clinicopathological report: bilateral choroidal metastases from papillary thyroid cancer. Asia Pac. J. Clin. Oncol., 2011, 7(1), 11-14.
[http://dx.doi.org/10.1111/j.1743-7563.2010.01332.x] [PMID: 21332645]
[111]
Makhija, C.; Su, Y.B.; Goldner, W. Unusual Case of Papillary Thyroid Carcinoma with Choroidal Metastasis. Thyroid, 2015, 25(7), 860-864.
[http://dx.doi.org/10.1089/thy.2014.0511] [PMID: 25872533]
[112]
D’Avanzo, A.; Treseler, P.; Ituarte, P.H.G.; Wong, M.; Streja, L.; Greenspan, F.S.; Siperstein, A.E.; Duh, Q.Y.; Clark, O.H. Follicular thyroid carcinoma: histology and prognosis. Cancer, 2004, 100(6), 1123-1129.
[http://dx.doi.org/10.1002/cncr.20081] [PMID: 15022277]
[113]
McHenry, C.R.; Phitayakorn, R. Follicular adenoma and carcinoma of the thyroid gland. Oncologist, 2011, 16(5), 585-593.
[http://dx.doi.org/10.1634/theoncologist.2010-0405] [PMID: 21482585]
[114]
Betharia, S.M. Metastatic orbital carcinoma of thyroid. Indian J. Ophthalmol., 1985, 33(3), 191-193.
[PMID: 3841868]
[115]
Shyla, P.R.; Nair, R.M.; Somanathan, T. Rare case of orbital tumor. Indian J. Otolaryngol. Head Neck Surg., 2007, 59(2), 174-175.
[http://dx.doi.org/10.1007/s12070-007-0052-z] [PMID: 23120424]
[116]
Bernstein-Lipschitz, L.; Lahav, M.; Chen, V.; Gutman, I.; Gal, R.; Lipschitz, M. Metastatic thyroid carcinoma masquerading as lacrimal gland tumor. Graefes Arch. Clin. Exp. Ophthalmol., 1990, 228(2), 112-115.
[http://dx.doi.org/10.1007/BF00935717] [PMID: 2186969]
[117]
Boughattas, S.; Chatti, K.; Degdegui, M.; Bouslama, Z.; Elaouni, C. Uncommon case of orbital metastasis secondary to papillary thyroid carcinoma. Thyroid, 2005, 15(11), 1311-1312.
[http://dx.doi.org/10.1089/thy.2005.15.1311] [PMID: 16356099]
[118]
Daumerie, C.; De Potter, P.; Godfraind, C.; Rahier, J.; Jamar, F.; Squifflet, J.P. Orbital metastasis as primary manifestation of thyroid carcinoma. Thyroid, 2000, 10(2), 189-192.
[http://dx.doi.org/10.1089/thy.2000.10.189] [PMID: 10718558]
[119]
Pagsisihan, D.A.; Aguilar, A.H.I.; Maningat, M.P.D.D. Orbital metastasis as initial manifestation of a widespread papillary thyroid microcarcinoma. B.M.J. Case Rep, 2015, 2015
[http://dx.doi.org/10.1136/bcr-2014-208870]
[120]
Malhotra, G.; Upadhye, T.S.; Menon, S.; Asopa, R.V.; Laskar, S.G.; Pawar, S.; Bhagat, J.K.; Joshi, P. Unilateral proptosis due to orbital metastasis as a presenting clinical manifestation of carcinoma of the thyroid. Clin. Nucl. Med., 2010, 35(5), 362-365.
[http://dx.doi.org/10.1097/RLU.0b013e3181d62752] [PMID: 20395717]
[121]
Tijl, J.; Koornneef, L.; Eijpe, A.; Thomas, L.; Gonzalez, D.G.; Veenhof, C. Metastatic tumors to the orbit--management and prognosis. Graefes Arch. Clin. Exp. Ophthalmol., 1992, 230(6), 527-530.
[http://dx.doi.org/10.1007/BF00181773] [PMID: 1427135]
[122]
Goldberg, R.A.; Rootman, J.; Cline, R.A. Tumors metastatic to the orbit: a changing picture. Surv. Ophthalmol., 1990, 35(1), 1-24.
[http://dx.doi.org/10.1016/0039-6257(90)90045-W] [PMID: 2204127]
[123]
Goldberg, R.A.; Rootman, J. Clinical characteristics of metastatic orbital tumors. Ophthalmology, 1990, 97(5), 620-624.
[http://dx.doi.org/10.1016/S0161-6420(90)32534-4] [PMID: 2342807]
[124]
Kennerdell, J.S.; Dekker, A.; Johnson, B.L.; Dubois, P.J. Fine-needle aspiration biopsy. Its use in orbital tumors. Arch. Ophthalmol., 1979, 97(7), 1315-1317.
[http://dx.doi.org/10.1001/archopht.1979.01020020057013] [PMID: 454270]
[125]
Basaria, S.; Cooper, D.S. Amiodarone and the thyroid. Am. J. Med., 2005, 118(7), 706-714.
[http://dx.doi.org/10.1016/j.amjmed.2004.11.028] [PMID: 15989900]
[126]
Wiersinga, W.M.; Trip, M.D. Amiodarone and thyroid hormone metabolism. Postgrad. Med. J., 1986, 62(732), 909-914.
[http://dx.doi.org/10.1136/pgmj.62.732.909] [PMID: 3774722]
[127]
Martino, E.; Bartalena, L.; Bogazzi, F.; Braverman, L.E. The effects of amiodarone on the thyroid. Endocr. Rev., 2001, 22(2), 240-254.
[PMID: 11294826]
[128]
Benjamens, S.; Dullaart, R.P.F.; Sluiter, W.J.; Rienstra, M.; van Gelder, I.C.; Links, T.P. The clinical value of regular thyroid function tests during amiodarone treatment. Eur. J. Endocrinol., 2017, 177(1), 9-14.
[http://dx.doi.org/10.1530/EJE-17-0018] [PMID: 28424174]
[129]
Martino, E.; Aghini-Lombardi, F.; Bartalena, L.; Grasso, L.; Loviselli, A.; Velluzzi, F.; Pinchera, A.; Braverman, L.E. Enhanced susceptibility to amiodarone-induced hypothyroidism in patients with thyroid autoimmune disease. Arch. Intern. Med., 1994, 154(23), 2722-2726.
[http://dx.doi.org/10.1001/archinte.1994.00420230115013] [PMID: 7993156]
[130]
Wiersinga, W.M. The role of thyroid hormone nuclear receptors in the heart: evidence from pharmacological approaches. Heart Fail. Rev., 2010, 15(2), 121-124.
[http://dx.doi.org/10.1007/s10741-008-9131-9] [PMID: 19096930]
[131]
Bogazzi, F.; Bartalena, L.; Martino, E. Approach to the patient with amiodarone-induced thyrotoxicosis. J. Clin. Endocrinol. Metab., 2010, 95(6), 2529-2535.
[http://dx.doi.org/10.1210/jc.2010-0180] [PMID: 20525904]
[132]
Ahmed, S.; Van Gelder, I.C.; Wiesfeld, A.C.; Van Veldhuisen, D.J.; Links, T.P. Determinants and outcome of amiodarone-associated thyroid dysfunction. Clin. Endocrinol. (Oxf.), 2011, 75(3), 388-394.
[http://dx.doi.org/10.1111/j.1365-2265.2011.04087.x] [PMID: 21535072]
[133]
Yagishita, A.; Hachiya, H.; Kawabata, M.; Nakamura, T.; Sugiyama, K.; Tanaka, Y.; Sasano, T.; Isobe, M.; Hirao, K. Amiodarone-induced thyrotoxicosis late after amiodarone withdrawal. Circ. J., 2013, 77(12), 2898-2903.
[http://dx.doi.org/10.1253/circj.CJ-13-0220] [PMID: 24042320]
[134]
Flach, A.J.; Dolan, B.J.; Sudduth, B.; Weddell, J. Amiodarone-induced lens opacities. Arch. Ophthalmol., 1983, 101(10), 1554-1556.
[http://dx.doi.org/10.1001/archopht.1983.01040020556010] [PMID: 6626008]
[135]
Kaplan, L.J.; Cappaert, W.E. Amiodarone keratopathy. Correlation to dosage and duration. Arch. Ophthalmol., 1982, 100(4), 601-602.
[http://dx.doi.org/10.1001/archopht.1982.01030030603011] [PMID: 7073573]
[136]
Mäntyjärvi, M.; Tuppurainen, K.; Ikäheimo, K. Ocular side effects of amiodarone. Surv. Ophthalmol., 1998, 42(4), 360-366.
[http://dx.doi.org/10.1016/S0039-6257(97)00118-5] [PMID: 9493278]
[137]
D’Amico, D.J.; Kenyon, K.R.; Ruskin, J.N. Amiodarone keratopathy: drug-induced lipid storage disease. Arch. Ophthalmol., 1981, 99(2), 257-261.
[http://dx.doi.org/10.1001/archopht.1981.03930010259007] [PMID: 6258544]
[138]
Hollander, D.A.; Aldave, A.J. Drug-induced corneal complications. Curr. Opin. Ophthalmol., 2004, 15(6), 541-548.
[http://dx.doi.org/10.1097/01.icu.0000143688.45232.15] [PMID: 15523201]
[139]
Gittinger, J.W., Jr; Asdourian, G.K. Papillopathy caused by amiodarone. Arch. Ophthalmol., 1987, 105(3), 349-351.
[http://dx.doi.org/10.1001/archopht.1987.01060030069028] [PMID: 3827710]
[140]
Ingram, D.V.; Jaggarao, N.S.; Chamberlain, D.A. Ocular changes resulting from therapy with amiodarone. Br. J. Ophthalmol., 1982, 66(10), 676-679.
[http://dx.doi.org/10.1136/bjo.66.10.676] [PMID: 7115651]
[141]
Cooper, D.S.; Laurberg, P. Hyperthyroidism in pregnancy. Lancet Diabetes Endocrinol., 2013, 1(3), 238-249.
[http://dx.doi.org/10.1016/S2213-8587(13)70086-X] [PMID: 24622372]
[142]
Mandel, S.J.; Cooper, D.S. The use of antithyroid drugs in pregnancy and lactation. J. Clin. Endocrinol. Metab., 2001, 86(6), 2354-2359.
[http://dx.doi.org/10.1210/jcem.86.6.7573] [PMID: 11397822]
[143]
Azizi, F. The safety and efficacy of antithyroid drugs. Expert Opin. Drug Saf., 2006, 5(1), 107-116.
[http://dx.doi.org/10.1517/14740338.5.1.107] [PMID: 16370960]
[144]
Andersen, S.L.; Olsen, J.; Laurberg, P. Antithyroid drug side effects in the population and in pregnancy. J. Clin. Endocrinol. Metab., 2016, 101(4), 1606-1614.
[http://dx.doi.org/10.1210/jc.2015-4274] [PMID: 26815881]
[145]
Clementi, M.; Di Gianantonio, E.; Cassina, M.; Leoncini, E.; Botto, L.D.; Mastroiacovo, P. SAFE-Med Study Group. Treatment of hyperthyroidism in pregnancy and birth defects. J. Clin. Endocrinol. Metab., 2010, 95(11), E337-E341.
[http://dx.doi.org/10.1210/jc.2010-0652] [PMID: 20668039]
[146]
Foulds, N.; Walpole, I.; Elmslie, F.; Mansour, S. Carbimazole embryopathy: an emerging phenotype. Am. J. Med. Genet, A, 2005, 132A(2), 130-135.
[147]
Andersen, S.L.; Olsen, J.; Wu, C.S.; Laurberg, P. Birth defects after early pregnancy use of antithyroid drugs: a Danish nationwide study. J. Clin. Endocrinol. Metab., 2013, 98(11), 4373-4381.
[http://dx.doi.org/10.1210/jc.2013-2831] [PMID: 24151287]
[148]
Andersen, S.L.; Laurberg, P. Antithyroid drugs and congenital heart defects: ventricular septal defect is part of the methimazole/carbimazole embryopathy. Eur. J. Endocrinol., 2014, 171(5), C1-C3.
[http://dx.doi.org/10.1530/EJE-14-0524] [PMID: 25069457]
[149]
Laurberg, P.; Andersen, S.L. Therapy of endocrine disease: antithyroid drug use in early pregnancy and birth defects: time windows of relative safety and high risk? Eur. J. Endocrinol., 2014, 171(1), R13-R20.
[http://dx.doi.org/10.1530/EJE-14-0135] [PMID: 24662319]
[150]
Momotani, N.; Noh, J.Y.; Ishikawa, N.; Ito, K. Effects of propylthiouracil and methimazole on fetal thyroid status in mothers with Graves’ hyperthyroidism. J. Clin. Endocrinol. Metab., 1997, 82(11), 3633-3636.
[PMID: 9360518]
[151]
Bliddal, S.; Rasmussen, A.K.; Sundberg, K.; Brocks, V.; Feldt-Rasmussen, U. Antithyroid drug-induced fetal goitrous hypothyroidism. Nat. Rev. Endocrinol., 2011, 7(7), 396-406.
[http://dx.doi.org/10.1038/nrendo.2011.34] [PMID: 21403664]
[152]
Chang, A.E.; Karnell, L.H.; Menck, H.R. The American College of Surgeons Commission on Cancer and the American Cancer Society. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer, 1998, 83(8), 1664-1678.
[http://dx.doi.org/10.1002/(SICI)1097-0142(19981015)83:8<1664:AID-CNCR23>3.0.CO;2-G] [PMID: 9781962]
[153]
Dummer, R.; Hauschild, A.; Guggenheim, M.; Keilholz, U.; Pentheroudakis, G. ESMO Guidelines Working Group. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol., 2012, 23(Suppl. 7), vii86-vii91.
[http://dx.doi.org/10.1093/annonc/mds229] [PMID: 22997461]
[154]
Dadu, R.; Zobniw, C.; Diab, A. Managing adverse events with immune checkpoint agents. Cancer J., 2016, 22(2), 121-129.
[http://dx.doi.org/10.1097/PPO.0000000000000186] [PMID: 27111908]
[155]
Corsello, S.M.; Barnabei, A.; Marchetti, P.; De Vecchis, L.; Salvatori, R.; Torino, F. Endocrine side effects induced by immune checkpoint inhibitors. J. Clin. Endocrinol. Metab., 2013, 98(4), 1361-1375.
[http://dx.doi.org/10.1210/jc.2012-4075] [PMID: 23471977]

Rights & Permissions Print Cite
Article Metrics
26
3
© 2024 Bentham Science Publishers | Privacy Policy